Surgery Partners, Inc. (NASDAQ:SGRY) announced it will release its fourth quarter 2025 earnings results on March 2, 2026, followed by a conference call on March 3, 2026 at 8:30 a.m. ET. The company, a leading short-stay surgical facility owner and operator with over 200 locations across 30 states, will provide investors with access to the call via phone and webcast.

Irenic Capital Management sold 1,047,583 shares of Surgery Partners (SGRY) in Q4 2025, reducing its stake to just 0.09% of assets. The stock has declined 39.7% over the past year, underperforming the S&P 500 by 51.61 percentage points. While the company's operations remain solid with 6.6% revenue growth, concerns center on high leverage with net debt to EBITDA at 4.2x-4.6x in a higher rate environment.

The global ambulatory surgical center (ASC) market is projected to grow from US$ 85.9 billion in 2024 to US$ 142.6 billion by 2033, driven by cost-effectiveness, favorable reimbursement policies, expanding CMS-approved procedures, and patient preference for outpatient surgeries. Physician-owned ASCs dominate with 59.56% market share, while North America leads globally with 26.46% share. Key growth factors include significant cost savings compared to hospital outpatient departments and technological advancements enabling more complex procedures.

Surgery Partners priced $425 million in senior unsecured notes due 2032, intending to use proceeds for general corporate purposes including repaying outstanding borrowings under its revolving credit facility.

AirSculpt Technologies appointed Mike Doyle as Non-Executive Chairman of its Board of Directors. Doyle brings over 30 years of leadership experience in multi-center healthcare and has previously led Surgery Partners and founded MD Healthcare Partners.

Surgery Partners experienced a significant stock drop of nearly 25% after reporting Q3 earnings that missed analyst expectations, with lower-than-anticipated non-GAAP earnings and revenue, despite a 7% year-over-year revenue growth.

Surgery Partners will release its Q3 2025 financial results on November 10, 2025, before market opening, followed by a conference call at 8:30 a.m. Eastern Time.

Surgery Partners reported Q2 2025 revenue of $826.2 million, an 8.4% year-over-year increase, with mixed financial results. The company saw strong case volume growth and reaffirmed full-year guidance, despite challenges with net losses and higher network growth costs.

Surgery Partners will release its second quarter 2025 financial results on August 5, 2025, with a conference call at 8:30 a.m. Eastern Time, providing investors an opportunity to hear about the company's performance.

Surgery Partners, Inc. has received a non-binding acquisition proposal from Bain Capital to acquire all outstanding shares not already owned by Bain Capital for $25.75 per share. A special committee of independent directors will consider the proposal with the assistance of advisors.

Netflix reported mixed Q2 results, with better-than-expected earnings but weaker guidance. Intuitive Surgical saw strong Q2 results, with a 17% increase in procedures. Plug Power announced a $200 million stock offering, while Surgery Partners is exploring strategic options including a potential sale.

In the latest quarter, 4 analysts provided ratings for Surgery Partners (NASDAQ:SGRY), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Surgery Partners, presenting an average target of $40.5, a high estimate of $50.00, and a low estimate of $31.00. Observing a downward trend, the current average is 11.96% lower than the prior average price target of $46.00. Diving into Analyst Ratings: An In-Depth Exploration The standing of Surgery Partners among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Tao Qiu Macquarie Announces Outperform $31.00 - Jason Cassorla Citigroup Lowers Buy $38.00 $42.00 Bill Sutherland Benchmark Maintains Buy $50.00 $50.00 Sarah James Cantor Fitzgerald Maintains Overweight $43.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Surgery ...Full story available on Benzinga.com